Prime Medicine, Inc. Common Stock (PRME) - Total Assets
Based on the latest financial reports, Prime Medicine, Inc. Common Stock (PRME) holds total assets worth $385.01 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Prime Medicine, Inc. Common Stock book value and equity for net asset value and shareholders' equity analysis.
Prime Medicine, Inc. Common Stock - Total Assets Trend (2019–2024)
This chart illustrates how Prime Medicine, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
Prime Medicine, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Prime Medicine, Inc. Common Stock's total assets of $385.01 Million consist of 71.2% current assets and 28.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 61.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Prime Medicine, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PRME stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Prime Medicine, Inc. Common Stock's current assets represent 71.2% of total assets in 2024, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 61.3% of total assets in 2024, down from 99.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Prime Medicine, Inc. Common Stock Competitors by Total Assets
Key competitors of Prime Medicine, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Prime Medicine, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.61 | 6.50 | 2.75 |
| Quick Ratio | 6.61 | 6.50 | 2.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $196.39 Million | $208.19 Million | $33.96 Million |
Prime Medicine, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Prime Medicine, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.70 |
| Latest Market Cap to Assets Ratio | 2.00 |
| Asset Growth Rate (YoY) | 53.5% |
| Total Assets | $297.51 Million |
| Market Capitalization | $595.69 Million USD |
Valuation Analysis
Above Book Valuation: The market values Prime Medicine, Inc. Common Stock's assets above their book value (2.00x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Prime Medicine, Inc. Common Stock's assets grew by 53.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Prime Medicine, Inc. Common Stock (2019–2024)
The table below shows the annual total assets of Prime Medicine, Inc. Common Stock from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $297.51 Million | +53.47% |
| 2023-12-31 | $193.85 Million | -46.20% |
| 2022-12-31 | $360.31 Million | +19.37% |
| 2021-12-31 | $301.86 Million | +451.00% |
| 2020-12-31 | $54.78 Million | +529.91% |
| 2019-12-31 | $8.70 Million | -- |
About Prime Medicine, Inc. Common Stock
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that… Read more